Peptide LibraryVK2735
VK2735 is a GIP receptor agonist in the GLP-1 Agonist class. VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
For research use only.
Key Facts
- CAS
- —
- Molecular Weight (MW)
- —
- Half-life
- —
- FDA status
- Investigational New Drug (IND)
- Evidence level
- Clinical Trial Evidence
- Human dose established
- Yes
- Administration Route
- Subcutaneous · Oral (separate daily tablet form, phase 2)
- Frequency
- Once weekly (injection); once daily (oral form)
- Last updated
- Nov 7, 2026
- Reviewed
- Nov 7, 2026
Research summary
Investigational dual agonist of the GLP-1 and GIP receptors in clinical development for obesity and metabolic disease, in both injectable and oral formulations. Not FDA-approved.
Research evidence
- Regulatory review (FDA label)None in reviewed sources
- Controlled human trials2 reviewed sources
- Early or uncontrolled human studiesNone in reviewed sources
- Lab & animal studiesNone in reviewed sources
How it works
Each step shows whether the sources Peptide Library has reviewed include that kind of research. Counts are reviewed sources, not every study ever published. Reviews and programme summaries that describe human use are shown as "reported", not as trials, and registered trials without published results are listed but not counted. A higher step means research has progressed further; it does not mean a compound works better or is safer. Compounds whose evidence has not been reviewed yet show "Not reviewed" instead of a guess.
Peptide Library's VK2735 profile summarises 5 cited studies listed in the Science section, the compound's regulatory status, and research-protocol parameters reported for it. It is a research reference, not medical advice.
VK2735 dosage evidence
VK2735 has no approved dosage. Published human dosing comes from the phase 2 VENTURE trial, which gave once-weekly injections under the skin from 2.5 mg to 15 mg for 13 weeks to adults with obesity or overweight without diabetes; mean weight loss ranged from 9.1% to 14.7% against 1.7% with placebo. Phase 3 trials of 7.5, 12.5 and 17.5 mg weekly are under way, and an oral daily form has been tested in phase 2.
| Human dosing established | Yes |
|---|---|
| Studied dose range | 2.5–15 mg once weekly in the phase 2 trial; 7.5–17.5 mg weekly in ongoing phase 3 |
| Route | Subcutaneous · Oral (separate daily tablet form, phase 2) |
| Frequency | Once weekly (injection); once daily (oral form) |
| Duration studied | 13 weeks in the published phase 2 trial |
| Titration | The VENTURE abstract reports titration to steady state; the step schedule is not given in the indexed abstract. |
| Evidence level | Clinical Trial Evidence |
| Last reviewed | 2026-11-07 |
Research-reported dosing
Doses as studied, one row per regimen. Different trials used different regimens; they are listed separately rather than averaged.
| Study / context | Population | Dose | Route | Frequency | Duration | Outcome studied | Source |
|---|---|---|---|---|---|---|---|
| VENTURE — phase 2, weekly injection (NCT06068946)Clinical trial · Randomized, double-blind, placebo-controlled phase 2 dose-ranging trial | Adults with obesity, or overweight with a weight-related condition, without diabetes (174 in the reported groups) | 2.5 mg to 15 mg (four dose groups) | Subcutaneous | Once weekly | 13 weeks | Mean weight loss from 9.1% (2.5 mg) to 14.7% (15 mg) against 1.7% with placebo; mostly gastrointestinal side effects | Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study. Obesity (Silver Spring). 2026. |
| VANQUISH — phase 3, weight management (NCT07104500)Clinical trial · Phase 3 randomized, placebo-controlled trial, active not recruiting | Adults with obesity or overweight (n=4,500 planned) | 7.5, 12.5 or 17.5 mg | Subcutaneous | Once weekly | Per trial protocol | Ongoing; no results posted | NCT07104500 — VK2735 for Weight Management Phase 3 |
| VENTURE-Oral — phase 2, daily tablet (NCT06828055)Clinical trial · Phase 2 randomized, placebo-controlled trial | Adults with obesity or overweight (n=280) | Six oral dose arms; amounts not given in the registry | Oral | Once daily | Per trial protocol | Completed; no results posted on ClinicalTrials.gov | NCT06828055 — VK2735 for Weight Management Phase 2 (Venture Oral Dosing) |
Where sources disagree
- The only peer-reviewed efficacy data are from a 13-week trial. Longer-term effects at these doses come from phase 3 trials that have not reported.
- VK2735 pairs GLP-1 and GIP agonism like tirzepatide, but its milligram doses are its own trial arms and are not interchangeable with tirzepatide doses.
- The oral and injected forms use different doses; an injected dose does not translate to an oral one, or the reverse.
Science
Mechanism of Action
VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
Studies
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study
- Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? (class-level evidence)
- Tirzepatide for overweight and obesity management (class-level evidence)
- Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? (class-level evidence)
- Cardiovascular effects of tirzepatide (class-level evidence)
Research statistics
1 PubMed publications · 100.0% human clinical research · 8 registered trials
Counts of published research through 2026-11-01, not evidence that it works. Publications by year, study types and trials · How publications are counted
Regulatory & research status
VK2735 has been studied under an Investigational New Drug application. It is not approved for marketing.
| FDA status | Investigational New Drug (IND) |
|---|---|
| Research status | Investigational; clinical development reported |
| Availability | Research-Only |
| WADA (sport) | Unknown / Not Listed |
| Library classification | Clinical Trial |
How FDA approval, compounding and research-only status differ
Benefits
—
VK2735 side effects
No side effects listed yet for this entry.
Storage & stability
This compound is not supplied as a powder to be mixed, so the freeze-dried powder and reconstitution handling described for research peptides does not apply. Storage conditions are product-specific: follow the label or packaging of the product itself.
VK2735: frequently asked questions
What is VK2735?
Investigational dual agonist of the GLP-1 and GIP receptors in clinical development for obesity and metabolic disease, in both injectable and oral formulations. Not FDA-approved.
How does VK2735 work?
VK2735 co-activates the GLP-1 and GIP receptors, the same pairing as tirzepatide. GLP-1 receptor activation slows gastric emptying, enhances glucose-dependent insulin secretion and reduces appetite through hypothalamic and brainstem circuits, while GIP receptor activation contributes additional effects on insulin secretion and adipose tissue metabolism that appear to add to weight reduction beyond GLP-1 alone.
Is VK2735 FDA approved?
No. VK2735 is investigational: it is in clinical development and has not been approved by the FDA for any indication. Investigational status means trials are ongoing or complete but regulatory review has not resulted in approval, and efficacy and safety are still being established.
What peptides are similar to VK2735?
Compounds most often compared with VK2735 include Tirzepatide, Ecnoglutide, Efpeglenatide and Semaglutide. They are grouped by shared mechanism or research area rather than by equivalence, and their regulatory status and evidence base differ.
References
- Weekly Subcutaneous VK2735, a GIP/GLP-1 Receptor Dual Agonist, for Weight Management: Phase 2, Randomized, 13-Week VENTURE Study — Obesity (Silver Spring), 2026External reference
- Class-level evidence — Incretin-Based Weight Loss Pharmacotherapy: Can Resistance Exercise Optimize Changes in Body Composition? — Diabetes Care, 2024External reference
- Class-level evidence — Tirzepatide for overweight and obesity management — Expert Opin Pharmacother, 2025External reference
- Class-level evidence — Why does GLP-1 agonist combined with GIP and/or GCG agonist have greater weight loss effect than GLP-1 agonist alone in obese adults without type 2 diabetes? — Diabetes Obes Metab, 2025External reference
- Class-level evidence — Cardiovascular effects of tirzepatide — J Endocrinol, 2025External reference
Related research, comparisons & guides
Related peptides
Compiled by Peptide Library Editorial · Reviewed Aug 30, 2026 · Updated Nov 7, 2026 · Version 2
This VK2735 profile is compiled from published literature (5 cited studies linked above), public regulatory records and chemical registries. It describes what research reports; it is not medical advice, and nothing here is a dosing recommendation for humans. Peptide Library does not sell peptides. Editorial policy · How profiles are compiled · Report an error
Track VK2735 research, inventory and reconstitution in the free Peptide Library app. Get the app for iOS or Android →